ReviewCurrent treatment options in oncology2014
New treatments for bladder cancer: when will we make progress?
Review in Current treatment options in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 20 citations in OpenAlex.
- CuOTeDsP nanotherapeutics enhance cuproptosis-mediated immunotherapy by modulating cholesterol metabolism in bladder cancer.Journal of nanobiotechnology · 2025Article
- Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer.Frontiers in oncology · 2021Article
- Role of Curcumin and (-)-Epigallocatechin-3-Cancers · 2020Review
- Identification of an Individualized Prognostic Signature Based on the RWSR Model in Early-Stage Bladder Carcinoma.BioMed research international · 2020Article
- The continuing role of chemotherapy in the management of advanced urothelial cancer.Therapeutic advances in urology · 2018Review
- Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.BMC cancer · 2016Article
- Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma.Bladder cancer (Amsterdam, Netherlands) · 2016Article
- Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.Neoplasia (New York, N.Y.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementThe prognosis and long-term survival for patients with metastatic urothelial carcinoma patients is poor. Traditionally, the mainstay of treatment has been combination chemotherapy with gemcitabine and cisplatin or with the classical M-VAC. Vinflunine has become an EMA-approved second-line option in Europe. Urothelial carcinomas contain genetic alteration in multiple genes that are potentially treated by targeted therapies. Recently, a number of these new therapies have been developed in this disease. But not one has been approved for clinical use in urothelial cancers. While clinical evaluation of these agents is still in its early days, some promising findings have begun to emerge. For example, everolimus demonstrated activity in those metastatic urothelial cancer patients who harbors TSC1 mutation. With the identification of the most relevant drug targets for tumors initiation and maintenance and the best way to assess drug candidates that may only account for a small fraction of patients, it is anticipated that the therapeutic arsenal for urothelial cancers will be expanded in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.